|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...4748495051525354555657...6566» |
- | Mycidac-C (mycobacterium indicus pranii heat-killed) / Cadila
Trial completion, Immunomodulating: Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients. (clinicaltrials.gov) - Apr 24, 2013
P3, N=300, Completed, Sponsor: Ministry of Science and Technology, India
Recruiting --> Completed
- || Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi, Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
New P3 trial: Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010) (clinicaltrials.gov) - Apr 22, 2013
P3, N=385, Active, not recruiting, Sponsor: Sanofi Pasteur MSD
- | Trial completion: Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 and 2 (clinicaltrials.gov) - Apr 22, 2013
P2, N=45, Completed, Sponsor: Thallion Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- || Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
New P3 trial: Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination (clinicaltrials.gov) - Apr 22, 2013
P3, N=350, Active, not recruiting, Sponsor: Sanofi Pasteur MSD
- ||||| AMG 108 / AstraZeneca
New P2a trial: Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Apr 22, 2013
P2a, N=100, Recruiting, Sponsor: AstraZeneca
- Trial initiation date: Clinical Trials to Reduce the Risk of Antimicrobial Resistance (clinicaltrials.gov) - Apr 17, 2013
P2, N=480, Recruiting, Sponsor: University of Florida
Active, not recruiting --> Completed Initiation date: Sep 2012 --> Jan 2013
- Enrollment open: Clinical Trials to Reduce the Risk of Antimicrobial Resistance (clinicaltrials.gov) - Apr 17, 2013
P2, N=480, Recruiting, Sponsor: University of Florida
Initiation date: Sep 2012 --> Jan 2013 Not yet recruiting --> Recruiting
- Mycobutin (rifabutin) / Pfizer, Lupin
Enrollment change: Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications (clinicaltrials.gov) - Apr 16, 2013
P=N/A, N=63, Completed, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting N=46 --> 63
- Mycobutin (rifabutin) / Pfizer, Lupin
Trial completion: Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications (clinicaltrials.gov) - Apr 16, 2013
P=N/A, N=63, Completed, Sponsor: University of California, San Francisco
N=46 --> 63 Active, not recruiting --> Completed
- trimethoprim/sulfamethoxazole / Generic mfg.
New P2 trial: Pharmacokinetic Parameters of Co-trimoxazole (clinicaltrials.gov) - Apr 14, 2013
P2, N=12, Recruiting, Sponsor: University Medical Centre Groningen
- ||||||| Cayston (aztreonam lysine) / Gilead
Trial completion: Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways (clinicaltrials.gov) - Apr 14, 2013
P3, N=61, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment closed: A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China (clinicaltrials.gov) - Apr 11, 2013
P3, N=1674, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania (clinicaltrials.gov) - Apr 11, 2013
P4, N=350, Completed, Sponsor: Johns Hopkins University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment closed: Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) (clinicaltrials.gov) - Apr 10, 2013
P2, N=105, Active, not recruiting, Sponsor: Global Alliance for TB Drug Development
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Trial completion: Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE (clinicaltrials.gov) - Apr 9, 2013
P4, N=278, Completed, Sponsor: Sanofi Pasteur MSD
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- moxifloxacin ophthalmic / Generic mfg.
Trial completion: Steroids for Corneal Ulcers Trial (clinicaltrials.gov) - Apr 9, 2013
P4, N=500, Completed, Sponsor: Thomas M. Lietman
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New P1 trial: Safety Study of ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy Adults (clinicaltrials.gov) - Apr 9, 2013
P1, N=30, Recruiting, Sponsor: University of Oxford
- pretomanid (PA-824) / Global Alliance for TB Drug Development
New P1 trial: CL-003: Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (clinicaltrials.gov) - Apr 9, 2013
P1, N=16, Completed, Sponsor: Global Alliance for TB Drug Development
- ||||||| Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
Trial completion: Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007) (clinicaltrials.gov) - Apr 8, 2013
P3, N=1250, Completed, Sponsor: Sanofi Pasteur MSD
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | mupirocin / Generic mfg.
New P2 trial: Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants (clinicaltrials.gov) - Apr 7, 2013
P2, N=126, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Besivance (besifloxacin ophthalmic suspension) / Bausch Health
Trial termination: Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis (clinicaltrials.gov) - Apr 4, 2013
P3, N=33, Terminated, Sponsor: Bausch & Lomb Incorporated
Active, not recruiting --> Completed Recruiting --> Terminated; Lack of enrollment
- Enrollment change: Bacterial Vaginosis in Pregnancy: Detection by Weekly Vaginal pH Testing (clinicaltrials.gov) - Apr 3, 2013
P=N/A, N=1049, Completed, Sponsor: Montse Palacio
Recruiting --> Terminated; Lack of enrollment N=3600 --> 1049
- Trial completion: Bacterial Vaginosis in Pregnancy: Detection by Weekly Vaginal pH Testing (clinicaltrials.gov) - Apr 3, 2013
P=N/A, N=1049, Completed, Sponsor: Montse Palacio
N=3600 --> 1049 Recruiting --> Completed
- |||| Sirturo (bedaquiline) / J&J, Pharmstandard
Trial completion: To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB. (clinicaltrials.gov) - Apr 2, 2013
P2, N=241, Completed, Sponsor: Janssen Infectious Diseases BVBA
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| New P4 trial: Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose (clinicaltrials.gov) - Apr 2, 2013
P4, N=465, Completed, Sponsor: Novartis Vaccines
- New P1/2 trial: PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera (clinicaltrials.gov) - Apr 2, 2013
P1/2, N=26, Completed, Sponsor: PATH
- ondansetron / Generic mfg.
Trial withdrawal: ITT-MAC: Improving Tolerance of Treatment of Pulmonary MAC Infections (clinicaltrials.gov) - Apr 1, 2013
P2, N=0, Withdrawn, Sponsor: University of Florida
Active, not recruiting --> Completed Recruiting --> Withdrawn
- ondansetron / Generic mfg.
Enrollment change: ITT-MAC: Improving Tolerance of Treatment of Pulmonary MAC Infections (clinicaltrials.gov) - Apr 1, 2013
P2, N=0, Withdrawn, Sponsor: University of Florida
Recruiting --> Withdrawn N=32 --> 0
- Enrollment closed: Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis (clinicaltrials.gov) - Mar 31, 2013
P2, N=216, Active, not recruiting, Sponsor: Johns Hopkins University
N=32 --> 0 Recruiting --> Active, not recruiting
- || New P3 trial: Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients (clinicaltrials.gov) - Mar 27, 2013
P3, N=212, Terminated, Sponsor: Maastricht University Medical Center
- | azithromycin / Generic mfg.
Enrollment open: PregnAnZI: Prevention of Bacterial Infections in Newborn (clinicaltrials.gov) - Mar 27, 2013
P3, N=830, Recruiting, Sponsor: Medical Research Council Unit, The Gambia
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi
Enrollment closed: Database Surveillance Safety Study of PENTACEL® Vaccine (clinicaltrials.gov) - Mar 27, 2013
P=N/A, N=10000, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi
Trial completion: Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China (clinicaltrials.gov) - Mar 27, 2013
P4, N=900, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Trial completion: Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children (clinicaltrials.gov) - Mar 27, 2013
P4, N=666, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Urocidin (mycobacterium cell wall-DNA complex) / Liminal BioSci
Trial termination: EMBARC-RF: Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Mar 26, 2013
P3, N=84, Terminated, Sponsor: Bioniche Life Sciences Inc.
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Lack of Recruitment
- | Urocidin (mycobacterium cell wall-DNA complex) / Liminal BioSci
Enrollment change: EMBARC-RF: Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Mar 26, 2013
P3, N=84, Terminated, Sponsor: Bioniche Life Sciences Inc.
Active, not recruiting --> Terminated; Lack of Recruitment N=450 --> 84
- moxifloxacin intravenous / Generic mfg.
Trial completion: Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis (clinicaltrials.gov) - Mar 25, 2013
P2, N=170, Completed, Sponsor: Johns Hopkins University
N=450 --> 84 Active, not recruiting --> Completed
- Clinical: Bacteriophage Effects on Pseudomonas Aeruginosa (clinicaltrials.gov) - Mar 24, 2013
P=N/A, N=59, Completed, Sponsor: University Hospital, Montpellier
- | lanopepden (GSK1322322) / GSK
New P1 trial: A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects (clinicaltrials.gov) - Mar 24, 2013
P1, N=36, Recruiting, Sponsor: GlaxoSmithKline
- ||||| Onbrez (indacaterol) / Novartis
Enrollment change: INFINITY: Indacaterol EfectIveness In COPD Patients With Tuberculosis History (clinicaltrials.gov) - Mar 21, 2013
P3, N=132, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=76 --> 132
- |||||| Onbrez (indacaterol) / Novartis
Enrollment open: INFINITY: Indacaterol EfectIveness In COPD Patients With Tuberculosis History (clinicaltrials.gov) - Mar 21, 2013
P3, N=132, Recruiting, Sponsor: Novartis Pharmaceuticals
N=76 --> 132 Not yet recruiting --> Recruiting
- Gammaplex (intravenous normal human immunoglobulin) / Bio Products Lab
Enrollment closed: A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency (clinicaltrials.gov) - Mar 21, 2013
P4, N=25, Active, not recruiting, Sponsor: Bio Products Laboratory
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- mupirocin / Generic mfg.
Trial initiation date: HOME2DS: Individualized vs. Household MRSA Decolonization (clinicaltrials.gov) - Mar 20, 2013
P=N/A, N=600, Enrolling by invitation, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Initiation date: Jan 2013 --> Apr 2013
- |||| Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK
Enrollment open: Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea (clinicaltrials.gov) - Mar 20, 2013
P=N/A, N=3300, Recruiting, Sponsor: Novartis Vaccines
Initiation date: Jan 2013 --> Apr 2013 Not yet recruiting --> Recruiting
- ||||||| Trial completion: Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia (clinicaltrials.gov) - Mar 20, 2013
P3, N=198, Completed, Sponsor: Novartis Vaccines
Not yet recruiting --> Recruiting Recruiting --> Completed
- colistin sulphate / Generic mfg.
Trial completion: Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization (clinicaltrials.gov) - Mar 19, 2013
P2, N=10, Completed, Sponsor: University of Jena
Recruiting --> Completed Recruiting --> Completed
- mupirocin / Generic mfg.
Clinical: HOME2DS: Individualized vs. Household MRSA Decolonization (clinicaltrials.gov) - Mar 17, 2013
P=N/A, N=600, Enrolling by invitation, Sponsor: Washington University School of Medicine
- Clinical: Safety Study of Live Attenuated Oral Shigella (WRSS1) Vaccine in Bangladeshi Adults and Children (clinicaltrials.gov) - Mar 14, 2013
P=N/A, N=87, Not yet recruiting, Sponsor: Program for Appropriate Technology in Health
- Altabax (retapamulin) / GSK, Almirall
New P1 trial: Retapamulin Microdialysis Feasibility Study (clinicaltrials.gov) - Mar 14, 2013
P1, N=3, Not yet recruiting, Sponsor: GlaxoSmithKline
- |||||||||| Baxdela (delafloxacin) / Menarini, Melinta Therap
New P3 trial: Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Mar 13, 2013
P3, N=660, Recruiting, Sponsor: Melinta Therapeutics, Inc.